Elucidating the exact pharmacological system of motion (MOA) of naturally transpiring compounds can be demanding. Even though Tarselli et al. (60) created the initial de novo artificial pathway to conolidine and showcased this naturally developing compound effectively suppresses responses to both of those chemically induced and inflammation-derived